Generation
A deterministic zero-cost baseline produces reviewable English and Spanish packages.
Firequark software
Package Studio.
Fact-grounded content assembly.
Generate deterministic English and Spanish packages with exact evidence bindings, validation and review.
Package Studio status
- Current Track A software is technically complete and deployed as a controlled beta on the shared-host profile.
- The shared-host beta is explicitly non-production-grade; external reads and writes remain off by default.
- Synthetic and fictional records demonstrate software behavior, not customer results or market validation.
Fact-grounded content assembly
Generate deterministic English and Spanish packages with exact evidence bindings, validation and review.
Package Studio is part of Firequark Growth OS rather than a disconnected marketing service. Its workflows preserve review, tenant scope and evidence boundaries.
Capabilities
Inside Package Studio.
Binding
Material claims retain exact fact and evidence-version relationships.
Approval
Unsupported, untranslated or stale output cannot bypass validation and review.
Deployment profiles
One product contract,
two operating profiles.
| Profile | Use | Current boundary |
|---|---|---|
| DreamHost shared MVP | Internal use and authorized controlled beta | Static app, PHP API, SQLite, bounded cron; non-production-grade |
| Production profile | Future higher-scale operation | Next server, API, workers, PostgreSQL RLS, Redis and private objects; not publicly launched |
What remains external
Technical completion
is not market proof.
Real-user validation
Fixtures cannot satisfy paid activation, retention or customer-outcome gates.
Provider launch
Live messaging, publishing, ads, billing and other consequential providers require separate credentials and approval.
Production operation
Monitoring ownership, support, legal review, backups and production infrastructure remain launch decisions.
Ignition
Evaluate Package Studio with a guided proof-of-value.
The fixed-scope starting product is a 30-day controlled-beta evaluation with explicit boundaries and no invented result claims.